ESR1 and breast carcinoma: The primary conundrum in treatment and management of early stage estrogen receptor positive (ER+) breast cancer (BCa) is identifying which of these cancers are candidates for adjuvant chemotherapy and which patients will respond to hormonal therapy alone.